Stock listing
A2AGVE Stock Price, News, Filings & Events — Maxcyte, Inc.
Selected listing: A2AGVE · LSX · EUR · DE
This page tracks Maxcyte, Inc.'s A2AGVE:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2AGVE:LSX. A2AGVE:LSX is the stock-level entry point for investors researching Maxcyte, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2AGVE:LSX
- Asset type
- Stock
- Market cap
- $141.4M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LSX
- Currency
- EUR
Maxcyte, Inc. A2AGVE:LSX stock context
This page tracks Maxcyte, Inc.'s A2AGVE:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2AGVE:LSX. A2AGVE:LSX is the stock-level entry point for investors researching Maxcyte, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Maxcyte, Inc.
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
Maxcyte, Inc. earnings calls
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call
August 12, 2026 · Replay with transcript and chapters
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call
May 12, 2026 · Replay with transcript and chapters
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call
March 24, 2026 · Replay with transcript and chapters
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call
November 12, 2025 · Replay with transcript and chapters
MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call
August 6, 2025 · Replay with transcript and chapters
MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call
May 7, 2025 · Replay with transcript and chapters
Research Maxcyte, Inc.
Maxcyte, Inc. investor report
Review AI stock analysis and investor report context for A2AGVE:LSX.
Maxcyte, Inc. company profile
View the public company page for Maxcyte, Inc. on 6ix.
Maxcyte, Inc. news
Read company news and market updates connected to Maxcyte, Inc..
Maxcyte, Inc. investor events
Find investor webinars, events, and replay context for Maxcyte, Inc..
Alternate listings
MXCT:NASDAQ
US · USD
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MXCT:BOATS
US · USD
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
A2AGVE:LS
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MYE0:GETTEX
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MYE0:TRADEGATE
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MYE0:DUS
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MYE0:FWB
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MYE0:MUN
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.
MYE0:SWB
DE · EUR
Alternate listing for Maxcyte, Inc.; the primary context on this page is A2AGVE:LSX.